Managing hypertension using combination therapy

American Family Physician

Volumn 77, Issue 9, 2008, Pages

  Frank, Jennifer ^a,b  

^a University of Wisconsin   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDACTAZINE; ALDOSTERONE ANTAGONIST; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; AMLODIPINE BESYLATE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATENOLOL PLUS CHLORTALIDONE; AVALIDE; BENAZEPRIL; BENDROFLUMETHIAZIDE; BENDROFLUMETHIAZIDE PLUS NADOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL MALEATE PLUS FELODIPINE; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; EPLERENONE; EPROSARTAN; FOSINOPRIL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS PROPRANOLOL; HYDROCHLOROTHIAZIDE PLUS QUINAPRIL; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; METOPROLOL TARTRATE; OLMESARTAN; PERINDOPRIL; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL PLUS VERAPAMIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIRETIC; VALSARTAN; ANGIOTENSIN RECEPTOR;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; EDEMA; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MONOTHERAPY; PRACTICE GUIDELINE; PRIMARY PREVENTION; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; SECONDARY PREVENTION; STROKE; SYSTOLIC BLOOD PRESSURE; ALGORITHM; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG COMBINATION;

ALGORITHMS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY DISEASE; DIURETICS; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MYOCARDIAL INFARCTION; RECEPTORS, ANGIOTENSIN; STROKE;

EID: 45549083219     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Chobanian AV, Bakris GL, Black HR, et al., for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
2. Tedesco MA, Natale F, Calabro R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens (Greenwich). 2006;8(9):634-641.
3. Bakris GL, Weir MR, Black HR. Improving blood pressure control rates: is there more we can do? J Clin Hypertens (Greenwich). 2007;9(2):134-142.
4. Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens. 2004;17(6):495-501. (Pubitemid 38726163)
5. Lacourcière Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther. 2005;27(7):1013-1021. (Pubitemid 41262459)
6. Taylor AA. Combination drug treatment of hypertension: have we come full circle? Curr Cardiol Rep. 2004;6(6):421-426. (Pubitemid 39585759)
7. Giles TD. Rationale for combination therapy as initial treatment for hypertension. J Clin Hypertens (Greenwich). 2003;5(4)(suppl 3):4-11.
8. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med. 1996;156(17): 1969-1978. (Pubitemid 26318104)
9. Elliott WJ. Is fixed combination therapy appropriate for initial hypertension treatment? Curr Hypertens Rep. 2002;4(4):278-285.
10. Erdine S, Ari O, Zanchetti A, et al. ESH-ESC guidelines for the management of hypertension. Herz. 2006;31(4):331-338. (Pubitemid 44046496)
11. Messerli FH, Weir MR, Neutel JM. Combination therapy of amlodipine/ benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens. 2002;15(6):550-556. (Pubitemid 34596963)
12. Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D. Effi- cacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther. 2005;27(5):578-587. (Pubitemid 40835968)
13. Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol. 2006;17(12):3472-3481. (Pubitemid 44865289)
14. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack [published corrections appear in Lancet. 2001;358(9292):1556 and Lancet. 2002;359(9323):2120]. Lancet. 2001;358(9287):1033-1041.
15. Gallagher M, Perkovic V, Chalmers J. Diuretics: a modern day treatment option? Nephrology (Carlton). 2006;11(5):419-427.
16. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-2031. (Pubitemid 38781102)
17. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289(2):178 and JAMA. 2004;291(18):2196]. JAMA. 2002;288(23):2981-2997.
18. Wright JT Jr, Bakris G, Greene T, et al., for the African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial [published correction appears in JAMA. 2006;295(23):2726]. JAMA. 2002;288(19):2421-2431.
19. Drug information. MD Consult. http://home.mdconsult.com/das/pharm/view/ 68957037-2. Accessed December 10, 2007.
20. United States Food and Drug Administration. Human drugs. Center for Drug Evaluation and Research. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm. Accessed October 10, 2007.
21. Padilla MC, Armas-Hernández MJ, Hernández RH, Israili ZH, Valasco M. Update on diuretics in the treatment of hypertension. Am J Ther. 2007;14(2):154-160. (Pubitemid 46597653)
22. Weir MR, Crikelair N, Levy D, Rocha R, Kuturu V, Glazer R. Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9(2):103-112.
23. Sowers JR, Neutel JM, Saunders E, et al., for the INCLUSIVE Investigators. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006;8(7):470-480.
24. Hair PI, Scott LJ, Perry CM. Fixed-dose combination lercanidipine/ enalapril. Drugs. 2007;67(1):95-106. (Pubitemid 46105088)
25. Nash DT. Systolic hypertension. Geriatrics. 2006;61(12):22-28.
26. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. (Pubitemid 41265663)
27. Jamerson K, Bakris GL, Dahlöf B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007;16(2):80-86. (Pubitemid 47050368)
28. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007;49(1):12-26. (Pubitemid 44918179)
29. Williams B, Shaw A, Durrant R, Crinson I, Pagliari C, de Lusignan S. Patient perspectives on multiple medications versus combined pills: a qualitative study. QJM. 2005;98(12):885-893. (Pubitemid 43071455)
30. Ambrosioni E. Pharmacoeconomics of hypertension management: the place of combination therapy. Pharmacoeconomics. 2001;19(4): 337-347. (Pubitemid 32319928)
31. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) [published correction appears in J Am Coll Cardiol. 2006;47(7):1503-1505]. J Am Coll Cardiol. 2005;46(6):e1-e82.
32. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44(3):E1-E211. (Pubitemid 39036178)
33. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published corrections appear in N Engl J Med. 2000;342(18):1376, and N Engl J Med. 2000;342(10):748]. N Engl J Med. 2000;342(3):145-153.
34. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil- Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805-2816. (Pubitemid 37509488)
35. Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369(9571):1431-1439. (Pubitemid 46635780)
36. Tobe S, Kawecka-Jaszcz K, Zannad F, Vetrovec G, Patni R, Shi H. Amlodipine added to quinapril vs. quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial. J Clin Hypertens (Greenwich). 2007;9(2):120-127.
37. Bakris GL, Weir MR, for the Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003;5(3):202-209.
38. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317(7160):713-720. (Pubitemid 28414301)
39. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829-840. (Pubitemid 47362321)
40. Flack JM, Peters R, Mehra VC, Nasser SA. Hypertension in special populations. Cardiol Clin. 2002;20(2):303-319, vii. (Pubitemid 34803331)
41. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427. (Pubitemid 36776153)
42. Zamboli P, De Nicola L, Minutolo R, Bertino V, Catapano F, Conte G. Management of hypertension in chronic kidney disease. Curr Hypertens Rep. 2006;8(6):497-501. (Pubitemid 44842776)
43. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365(9463):939-946. (Pubitemid 41071427)
44. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension. 2005;45(5):880-886. (Pubitemid 40628932)
45. Schrader J, Lüders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36(6):1218-1226. (Pubitemid 40798742)